As per the research report, the size of the Europe Bleeding Disorders Treatment Market is valued at USD 2.89 billion in 2019 and is estimated to be growing at a CAGR of 7.75%, to reach USD 4.19 billion by 2024 during the forecast period 2019-2024.
The market is showcasing evident potential in the mentioned forecasting period. A bleeding disorder is a condition that affects the clotting (coagulation) system of the body. If not taken care of this condition properly, serious damage can happen to the body in case of any wound or cut due to excessive loss of blood from the body.
There are various types of Bleeding Disorders, but the most frequently seen cases are Hemophilia A, Hemophilia B, and von Willebrand Disease (vWD). A bleeding disorder is generally diagnosed by any of these three methods: Platelet Aggregation Test, Complete Blood Count (CBC) and bleeding time. There are various treatment methods depending on the type of bleeding disorder and its severity. Treatments include Iron Supplementation pills, Blood transfusion, and other methods.
R&D investment in this market in this region is very high leading to the latest technology and innovations. Also, the fact that most of the bleeding disorders are inherited and cannot be completely cured is also driving this market. On the other hand, factors such as high cost of treatment including medication and lack of skilled practitioners to cure these types of disorders are challenging this market.
This research report segmented and sub-segmented into the following categories:
The recombinant coagulation factor concentrates segment is expected to grow the fastest in the mentioned forecast period. This is because of the increased R&D in this market and the increasing focus of pharmaceutical companies on recombinant products.
Germany leads the market in this region both in terms of growth rate and market share followed by UK.
Key players operating in the Europe Bleeding Disorders Treatment Market profiled in this report are CSL Behring, Pfizer Inc., Novo Nordisk, Bayer AG, Biogen Inc., Shire Plc., Medline Plus, Janssen Europe Services, LLC and Grifos SA.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Introduction
5.1.2 Fibrin Sealant
5.1.3 Desmopressin
5.1.4 Antibrinolytics
5.1.5 Recombinant Coagulation Factor Concentrates
5.1.6 Plasma Derived Coagulation Factor Concentrates
5.1.7 Y-o-Y Growth Analysis, By Drug Class
5.1.8 Market Attractiveness Analysis, By Drug Class
5.1.9 Market Share Analysis, By Drug Class
5.2 Type
5.2.1 Introduction
5.2.2 vWD
5.2.3 Hemophilia A
5.2.4 Hemophilia B
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Class
6.1.3.3 By Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Class
6.1.4.3 By Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Class
6.1.5.3 By Type
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 CSL Behring
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer Inc.
8.3 Novo Nordisk
8.4 Bayer AG
8.5 Biogen Inc.
8.6 Shire Plc.
8.7 LLC
8.8 Medline Plus
8.9 Janssen Global Services
8.10 Grifos SA
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
